**Summary**
hVIVO plc, a leading early-phase Contract Research Organisation (CRO) and global leader in human challenge clinical trials, announced that its German subsidiary, CRS, has secured contracts worth over £5 million since September 2025. These contracts, signed with five clients including two returning mid-sized German pharma companies, reinforce CRSs strong reputation and long-standing relationships in Germany. The trials, spanning multiple therapeutic areas such as cardiometabolic, dermatology, infectious disease, renal impairment, and cancer, will commence in 2025 and H1 2026, with the majority of revenue recognized in 2026. This strengthens hVIVOs sales pipeline and order book for the coming years.
The contracts highlight the successful integration of CRS into the hVIVO Group, leveraging combined expertise and cross-selling opportunities, such as Venn Life Sciences Biometry services. CRSs enhanced participant recruitment platform, supported by hVIVOs Volunteer Management System, has improved efficiency in trial recruitment. Dr. Yamin Mo Khan, CEO of hVIVO, emphasized the strategic importance of CRS and its progress toward becoming earnings accretive in 2026. Professor Thomas Forst, Chief Medical Officer, underscored CRSs commitment to delivering high-quality clinical trial services that accelerate drug development.
hVIVO plc continues to expand its addressable market and strengthen its position as a leading partner in early-phase clinical research, offering fully integrated drug development solutions from preclinical stages through Phase II trials.